The 30-second summary
- Fatty liver is fat stored in liver cells. Its serious form, called MASH, causes inflammation and scarring, and it often has no symptoms until it is advanced.
- In trials, semaglutide and tirzepatide reduced liver fat, calmed inflammation, and in many people reversed early scarring. They are now the first medicines approved for MASH.
- You will not feel this working. That is the point. A liver problem you treat early is one you may never have to treat late.
What fatty liver actually is
Your liver is meant to store a little fat. When too much builds up, the condition is called fatty liver disease. The modern name is MASLD, metabolic dysfunction-associated steatotic liver disease, which is a long way of saying fat in the liver that comes from the same metabolic problems behind weight gain and high blood sugar.
For many people it stays mild and quiet. For some, the fat triggers inflammation and the liver begins to scar. That more serious stage is called MASH, metabolic dysfunction-associated steatohepatitis. Left alone for years, MASH can lead to permanent scarring (cirrhosis) and liver failure.
The hard part is that fatty liver is usually silent. No pain, no obvious sign, often discovered by accident on a scan or a blood test ordered for something else. Millions of people have it and do not know.
Why women on a GLP-1 should pay attention
Fatty liver travels with the same conditions that bring many women to a GLP-1 in the first place: extra weight, insulin resistance, type 2 diabetes, and PCOS. If any of those is part of your story, your odds of fatty liver are higher than average.
It is also under-diagnosed in women specifically. The cut-offs and screening habits were shaped largely around men, and women's liver disease is missed or caught later. After menopause the risk climbs again, as the metabolic protection of younger years fades.
So this is not a niche concern bolted on to a weight drug. For a large share of women on a GLP-1, the liver is quietly part of the same picture as the insulin resistance and the weight.
What changed in 2025 and 2026
Until recently there was no approved medicine for MASH. The only advice was lose weight, move more, and hope the scarring did not progress. That changed fast.
In 2025, semaglutide became an approved treatment for MASH on the strength of the ESSENCE trial, a large study showing it reduced liver inflammation and, in many patients, improved scarring. (Newsome et al., ESSENCE, NEJM 2025.)
Tirzepatide followed, supported by the SYNERGY-NASH trial, in which a majority of patients on the drug saw their MASH resolve without their scarring getting worse. (Loomba et al., SYNERGY-NASH, NEJM 2024.)
By May 2026, the European Association for the Study of Obesity had folded both drugs into its updated treatment framework as recommended options for resolving MASH. (EASO, 2026.) In the space of about a year, fatty liver went from a condition with no drug to a condition with two.
What the trials showed, plainly
Three things came through clearly.
Less fat in the liver. Both drugs cut liver fat substantially, measured directly on imaging, not guessed from weight.
Less inflammation. A majority of treated patients reached MASH resolution, meaning the active inflammation settled down. In ESSENCE, the semaglutide group did far better on this than placebo.
Less scarring, or at least no worse. This is the one that matters most for the long run. A meaningful share of patients saw early fibrosis improve, and most importantly, their scarring did not advance while on treatment.
These are not cosmetic numbers. They are the difference between a liver that quietly heals and one that quietly hardens.
What you would actually notice
Probably nothing, and that is fine. Because fatty liver is silent, treating it does not come with a feeling of relief the way easing nausea does. The win is invisible: a scan that looks better, a liver enzyme that drifts back toward normal, a future complication that never arrives.
If your prescriber has flagged fatty liver, the practical signals of progress are the boring ones. Liver enzymes (ALT and AST) trending down on a blood test. A follow-up scan showing less fat or stable scarring. These are worth asking about at your reviews, not waiting to be told.
What this does not mean
It does not mean a GLP-1 is a free pass for the liver. Alcohol still matters, and heavy drinking works directly against everything the drug is trying to do. Our guide on alcohol on a GLP-1 covers that in detail.
It does not mean you should start a GLP-1 to treat fatty liver on your own. Diagnosis and treatment of MASH belong with a clinician who can confirm the stage, usually with imaging or specialised tests, and follow it over time.
And it does not replace the foundation. Weight loss, protein to protect muscle, and movement remain the base the medication builds on, not a substitute for it.
What Steady helps you do
Steady does not test your liver. What it does is hold the surrounding picture steady, the dose you took and when, the weight trend over weeks rather than days, and the symptoms that come and go. When your prescriber orders liver tests or a scan, that record turns a five-minute appointment into a real conversation about whether the plan is working.
A silent condition needs a visible record. Steady is built to keep one.
Sources
- Newsome PN, Sanyal AJ, et al. Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). NEJM 2025. NEJM
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). NEJM 2024; 391:299-310. NEJM
- European Association for the Study of Obesity. Updated pharmacotherapy framework, MASH recommendations. 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases. Nonalcoholic Fatty Liver Disease and NASH. NIDDK
Medical disclaimer: This article is educational, not medical advice. Fatty liver and MASH must be diagnosed and managed by a qualified clinician. See our full medical disclaimer.